

A U D E A R A



Annual General Meeting
November 2021

A U D E A R A



Managing Director AGM Presentation
November 2021

Disclaimer

FORWARD LOOKING STATEMENTS

Audeara Limited (Audeara) makes no representation or warranty, either express or implied, in relation to the accuracy or completeness of the information contained within this ASX Presentation.


Statements and material contained in this ASX Presentation, particularly those regarding possible or assumed future performance or potential growth of Audeara, industry growth or other trend projections are, or may be, forward looking statements. Such statements relate to future events and expectations and are based on current expectations and beliefs. Such forward looking statements are not guarantees of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are outside the control of Audeara.

Graphs used in this ASX Presentation (including data used in the graphs) are sourced from third parties and Audeara has not independently verified the information. Although reasonable care has been taken to ensure that the facts stated in this ASX Presentation are accurate and or that the opinions expressed are fair and reasonable, no reliance can be placed for any purpose whatsoever on the information contained in this document or on its completeness. Actual results and developments may differ materially from those expressed or implied by these forward-looking statements depending on a variety of factors.

Nothing in this ASX Presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.



AUSTRALIAN CLINICS STOCKING AUDEARA – LEAD INDICATOR




- November 2021, Audeara has over 800 Audiology Clinics stocking A-01
- Actively pursuing commercial relationships with other large audiology clinic groups, which includes Audika and Specsavers, which offer the potential to materially grow the number of Australian audiology clinics stocking Audeara

Currently selling through:



AUSTRALIAN SALES

- CLINICS AND RETAIL



Strong sales growth driven by:

- Increasing number of clinics holding and selling stock
- Increasing volume sold by each clinic
- Becoming only headphone stocked in Amplifon Australia
- Increased focus on NDIS, attending key events and aligning with quality NDIS marketplaces



1. These figures are unaudited management prepared accounts for the purpose of discussing Audeara's customer mix in Australia
Calendar year quarters

US CLINIC GROWTH INITIATIVES

- Winner of the Hearing Health Matters Innovation Award at American Audiology Association Conference in Portland, Oregon – October 2021
- Primary sales focus remains on building relationships with key buying groups (who represent independent clinic groups)
 - Receiving positive feedback from first units shipped to clinics
 - In advanced conversations to launch initial test clinics
- First 500 A-01 TV Bundles shipped to US distributor to support sales initiatives
- Continuing to build our US sales capabilities
- Managing Director James Fielding relocating to USA for Q1 2022 to drive US growth



TECHNICAL UPDATE

- The next generation of Audeara's headphone products, the A-02s have completed preproduction and are undergoing device certification.
- Audeara has committed to the first mass production run and expect the A-02 to be commercially available in Q1 2022.
- The A-02 features are designed to improve device usability and simplify the initial setup.
- Desktop software; AudAssist will be released shortly, allowing audiologists and clinicians to personalise the headphones with a client's existing audiogram. The mobile version of AudAssist has been successfully trialed and the team is confident a desktop version will be more widely adopted.
- Chip supply chain made more secure by advanced purchase of high quantities of required chipsets and translation of technology away from low availability chipsets



A U D E A R A



Resolutions
November 2021

ONLINE ATTENDEES – VOTING PROCESS



When the poll is open, the vote will be accessible by selecting the voting icon at the top of the screen



To vote simply select the direction in which you would like to cast your vote. The selected option will change colour

For

Against

Abstain

There is no submit or send button, your selection is automatically recorded. You can change your mind or cancel your vote any time before the poll is closed

330-481-282

i

You have voted on 0 of 2 items

Resolution 1: Adoption of the Remuneration Report

Select a choice to send.

For	Against	Abstain
-----	---------	---------

CANCEL

Resolution 2: Approval of issue of securities under the Short-Term Incentive Plan

Select a choice to send.

For	Against	Abstain
-----	---------	---------

CANCEL



PROXY VOTING ON RESOLUTIONS

Resolution	Vote Type				
	For	Against	Open-Usable	Abstained	Excluded
1. Remuneration Report	18,973,335	50,000	47,692	9,675,157	23,927,420
2. Elect Pasquale Rombola	52,590,912	-	47,692	35,000	-
3. Re-elect David Trimboli	52,590,912	-	47,692	35,000	-
4. Appoint Company Auditor	52,590,912	-	47,692	35,000	-
5. App Additional 10% IC	42,570,667	35,000	47,692	10,020,245	-





A U D E A R A

Thank you